Clinical Trial

Fecal Microbiota Transplantation for Primary Sclerosing Cholangitis - Randomized Study Versus Sham Transplantation

Study acronym: FMT-SCLER
Not Yet Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
Primary Sclerosing Cholangitis (PSC) is a rare cholestatic liver disease, commonly associated with inflammatory bowel disease (IBD) The aim of the present trial is to assess the efficacy of fecal microbiota transplantation (FMT) on ALP and bilirubin compared to sham transplantation in addition to ursodeoxycholic acid (UDCA) treatment in PSC patients.
Trial Details
NCT Number NCT07477782
Lead Sponsor Assistance Publique - Hôpitaux de Paris
Conditions Primary Sclerosing Cholangitis (PSC), Inflammatory Bowel Disease (IBD)
Enrollment 72 participants
Start Date 2026-05
Primary Completion 2029-04 (estimated)
Study Completion 2030-05 (estimated)
Updated on ClinicalTrials.gov 2026-03-17